News
‘The story unfolding is worrisome’ for diabetes and COVID-19
May 28, 2020
Diabetes Care has published a host of new articles on diabetes and COVID-19 infection, as NIDDK researchers also acknowledge risks to other organ systems from the SARS-CoV-2 virus.
Opinion
Seek safe strategies to diagnose gestational diabetes during pandemic
May 27, 2020
Professional societies in the U.K., Canada, and Australia offer guidance to reduce risk while testing pregnant women for gestational diabetes during pandemic.
News
Glucose control linked to COVID-19 outcomes in largest-yet study
May 15, 2020
Wuhan researchers found preexisting type 2 diabetes worsened prognosis of COVID-19; but those whose glucose stayed “in-range” had better outcomes.
News
More guidance on inpatient management of blood glucose in COVID-19
May 7, 2020
Diabetes UK’s COVID-19 task force addresses inpatient use of subcutaneous insulin for managing hyperglycemia and ketoacidosis when IVs are unavailable.
News
FDA approves dapagliflozin for low-EF heart failure
May 7, 2020
The approval based on DAPA-HF makes dapagliflozin (Farxiga) the only drug in its class to be indicated for heart failure in the absence of diabetes.
News
New study of diabetes drug for COVID-19 raises eyebrows
May 1, 2020
Some question the safety of AstraZeneca’s just-launched DARE-19 study testing whether dapagliflozin will reduce adverse outcomes of COVID-19.
News
SGLT2 inhibitor ertugliflozin shows no CV death or renal benefit
April 29, 2020
Merck reports topline results from ertugliflozin’s FDA-mandated cardiovascular outcomes trial.
![1]()
News
COVID-19 cases highlight longstanding racial disparities in health care
April 16, 2020
Data on higher infection and death rates in African Americans from COVID-19 may serve as a call to action.
![1]()
News
Inflammatory markers may explain COVID-19, diabetes dynamic
April 15, 2020
Higher levels of markers may signal greater susceptibility to cytokine storm.
News
Dapagliflozin trial in CKD halted because of high efficacy
March 30, 2020
An independent data monitoring committee recommended stopping the trial.
